As on September 14, 2020, VYNE Therapeutics Inc. (NASDAQ: VYNE) got off with the flyer as it spiked 9.27% to $1.65. During the day, the stock rose to $1.74 and sunk to $1.53 before settling in for the price of $1.51 at the close. Taking a more long-term approach, VYNE posted a 52-week range of $1.00-$7.48.
Nevertheless, stock’s Earnings Per Share (EPS) this year is -30.30%. This publicly-traded company’s shares outstanding now amounts to $138.65 million, simultaneously with a float of $138.08 million. The organization now has a market capitalization sitting at $267.50 million. At the time of writing, stock’s 50-day Moving Average stood at $1.6051, while the 200-day Moving Average is $2.8911.
VYNE Therapeutics Inc. (VYNE) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. VYNE Therapeutics Inc.’s current insider ownership accounts for 2.10%, in contrast to 52.20% institutional ownership.
VYNE Therapeutics Inc. (VYNE) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 6/29/2020, the company posted -$0.14 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -$0.25) by $0.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
VYNE Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -30.30% and is forecasted to reach -0.38 in the upcoming year.
VYNE Therapeutics Inc. (NASDAQ: VYNE) Trading Performance Indicators
Let’s observe the current performance indicators for VYNE Therapeutics Inc. (VYNE). It’s Quick Ratio in the last reported quarter now stands at 4.70. The Stock has managed to achieve an average true range (ATR) of 0.12. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 19.96.
In the same vein, VYNE’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.75, a figure that is expected to reach -0.16 in the next quarter, and analysts are predicting that it will be -0.38 at the market close of one year from today.
Technical Analysis of VYNE Therapeutics Inc. (VYNE)
Through scrutinizing the latest numbers posted by the [VYNE Therapeutics Inc., VYNE], it can be observed that its last 5-days Average volume of 2.28 million was lower the volume of 2.8 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 63.89% While, its Average True Range was 0.1295.
Raw Stochastic average of VYNE Therapeutics Inc. (VYNE) in the period of the previous 100 days is set at 22.15%, which indicates a major fall in contrast to 79.55% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.88% that was lower than 77.86% volatility it exhibited in the past 100-days period.